2nd Quarter - Report

THE MCMANUS GROUP for GENENTECH

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to follow-on biologics. Support for H.R. 1548, "Pathway for Biosimilars Act." Opposition to H.R. 1427, "Promoting Innovation and Access to Life-Saving Medicine Act." Issues related to comparative effectiveness.

Foreign entity interest: 100% ownership by Roche Holding Ltd., 4070 Basel, Switzerland.

LobbyistCovered position, as disclosed
JOHN MCMANUS —
NICK SHIPLEY Legislative Director, Rep. Jay Inslee

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1548 (111th), H.R. 1427 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.